Xenikos Overview

  • Founded
  • 2009
  • Status
  • Private
  • Employees
  • 13
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $30M
Latest Deal Amount
  • Investors
  • 7

Xenikos General Information


Developer of anti-T-cell antibodies designed to develop innovative immunotherapy medicines to help restore patient's health. The company's antibodies use a therapeutic tool for resetting the body's immune system which once injected in the body, specifically identifies and eliminates adult T cells, with a strong preference for the activated ones, enabling patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system efficiently.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
  • Wilhelminasingel 14
  • 6524 AL Nijmegen
  • Netherlands
+31 024 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xenikos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 15-May-2018 $30M 000.00 Completed Generating Revenue
3. Grant 03-Jan-2017 00.000 00.00 Completed Generating Revenue
2. Later Stage VC 14-Oct-2016 $2.24M $9.1M Completed Generating Revenue
1. Early Stage VC (Series A) 19-Jun-2012 $6.9M $6.9M Completed Generating Revenue
To view Xenikos’s complete valuation and funding history, request access »

Xenikos Executive Team (7)

Name Title Board Seat Contact Info
Ypke van Oosterhout Ph.D Founder, Chief Executive Officer & Board Member
Maarten Frijlink Chief Operating Officer
Eric van Hooren Chief Development Officer
Hassan Aly MD Chief Medical Officer
Stanley Musial Chief Financial Officer & Chief Business Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Xenikos Board Members (15)

Name Representing Role Since
Derek DiRocco Ph.D RA Capital Management Board Observer 000 0000
Douglas Williams Ph.D Self Chairman 000 0000
Francesco De Rubertis Ph.D Medicxi Board Observer 000 0000
Jake Simson Ph.D RA Capital Management Board Member 000 0000
Jon Edwards Ph.D Medicxi Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Xenikos Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xenikos Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Medicxi Venture Capital Minority 000 0000 000000 0
Meneldor Venture Capital Minority 000 0000 000000 0
RA Capital Management Hedge Fund Minority 000 0000 000000 0
Stitching Participatie Xenikos Corporation Minority 000 0000 000000 0
Netherlands Enterprise Agency Government 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »